PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin

Am J Physiol Gastrointest Liver Physiol. 2015 Nov 15;309(10):G816-25. doi: 10.1152/ajpgi.00190.2015. Epub 2015 Sep 3.

Abstract

Pituitary adenylate cyclase-activating peptide (PACAP) is expressed within the gastroenteric system, where it has profound physiological effects. PACAP was shown to regulate food intake and thermogenesis centrally; however, PACAP peripheral regulation of appetite and feeding behavior is unknown. Therefore, we studied PACAP's effect on appetite and food intake control by analyzing feeding behavior and metabolic hormones in PAC1-deficient (PAC1-/-) and age-matched wild-type (WT) mice intraperitoneally injected with PACAP1-38 or PACAP1-27 before the dark phase of feeding. Food intake and feeding behavior were analyzed using the BioDAQ system. Active ghrelin, glucagon-like peptide-1 (GLP-1), leptin, peptide YY, pancreatic polypeptide, and insulin were measured following PACAP1-38 administration in fasted WT mice. PACAP1-38/PACAP1-27 injected into WT mice significantly decreased in a dose-dependent manner cumulative food intake and reduced bout and meal feeding parameters. Conversely, PACAP1-38 injected into PAC1-/- mice failed to significantly change food intake. Importantly, PACAP1-38 reduced plasma levels of active ghrelin compared with vehicle in WT mice. In PAC1-/- mice, fasting levels of active ghrelin, GLP-1, insulin, and leptin and postprandial levels of active ghrelin and insulin were significantly altered compared with levels in WT mice. Therefore, PAC1 is a novel regulator of appetite/satiety. PACAP1-38/PACAP1-27 significantly reduced appetite and food intake through PAC1. In PAC1-/- mice, the regulation of anorexigenic/orexigenic hormones was abolished, whereas active ghrelin remained elevated even postprandially. PACAP significantly reduced active ghrelin in fasting conditions. These results establish a role for PACAP via PAC1 in the peripheral regulation of appetite/satiety and suggest future studies to explore a therapeutic use of PACAP or PAC1 agonists for obesity treatment.

Keywords: GLP-1; PAC1 receptor; appetite; ghrelin; leptin; pituitary adenylate cyclase-activating peptide.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Appetite / drug effects
  • Appetite Regulation / physiology
  • Dose-Response Relationship, Drug
  • Eating / drug effects*
  • Feeding Behavior
  • Gastrointestinal Tract / metabolism
  • Ghrelin* / antagonists & inhibitors
  • Ghrelin* / blood
  • Glucagon-Like Peptide 1 / blood
  • Injections, Intraperitoneal
  • Leptin / metabolism*
  • Male
  • Mice
  • Models, Animal
  • Neurotransmitter Agents / administration & dosage
  • Neurotransmitter Agents / pharmacokinetics
  • Peptide YY / blood
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / administration & dosage
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / pharmacokinetics
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / metabolism*

Substances

  • Ghrelin
  • Leptin
  • Neurotransmitter Agents
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
  • Peptide YY
  • Glucagon-Like Peptide 1